Latest News for: hbv

Edit

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection (Aligos Therapeutics Inc)

Public Technologies 13 Jul 2026
The primary endpoint in the HBeAg+ part is HBV DNA ... Pevifoscorvir sodium is a potent potential best/first-in-class oral small molecule capsid assembly modulator (CAM-E) being developed for chronic hepatitis B virus (HBV) infection.
Edit

Aptima HIV Quant Dx Assay, HCV Quant Dx Assay, and HBV Quant Assay Software (CFIA - Canadian Food Inspection Agency)

Public Technologies 11 Jun 2026
Aptima HIV Quant Dx Assay, HCV Quant Dx Assay, and HBV Quant Assay Software ... Aptima HIV Quant Dx Assay, HCV Quant Dx Assay, and HBV Quant Assay Software ... Aptima HBV Quant Assay Kit Software v2.0.0.9 5.4.5.5.
Edit

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Continued HBsAg Declines, Without Rebound, Up ...

Business Wire 30 May 2026
... Cure, induced HBV-specific immune activation, restoration, and continued HBsAg declines, without .
Edit

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European ...

Image The Milton Standard Journal 27 May 2026
DURHAM, N.C.--(BUSINESS WIRE)--May 27, 2026-- ....
Edit

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 (Form 8-K) (Precision BioSciences Inc)

Public Technologies 27 May 2026
) Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 ... About PBGENE-HBV, A Viral Elimination Program.
Edit

Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV

PR Newswire 27 May 2026
Cohort 4 evaluated a novel sequential combination treatment strategy for HBV utilizing Brii Bio's therapeutic vaccine, BRII-179, to prime and enrich participants with a goal of improving responsiveness to curative therapies.
Edit

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented ...

Business Wire 21 May 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq.
Edit

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

Pharmiweb 21 May 2026
The ELIMINATE-B trial is evaluating PBGENE-HBV for the treatment of chronic hepatitis B ... About PBGENE-HBV, A Viral Elimination Program ... Elimination of cccDNA results in HBV viral cure as cccDNA is the only source of infectious replication (HBV DNA).
Edit

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of ...

Business Wire 22 Apr 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq ... The ELIMINATE-B trial is evaluating PBGEN .
Edit

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

Pharmiweb 22 Apr 2026
... Hepatitis B, cccDNA, while inactivating integrated HBV DNA; and the expectation that elimination of cccDNA could result in HBV cure as cccDNA is the only source of infectious replication (HBV DNA).
  • 1

Article Search

tools
×
×
×
×